Tellgen Corporation
300642.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.85B
Close$
$14.28
18.8% downside
Current Fair Value
18.8% downsideOvervalued by 18.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.85 Billion |
|---|---|
| Enterprise Value | $2.90 Billion |
| Dividend Yield | $0.10 (0.85%) |
| Earnings per Share | $0.02 |
| Beta | 0.32 |
| Outstanding Shares | 159,860,891 |
Return
| Return on Equity | 0.86% |
|---|---|
| Return on Assets | 0.61% |
| Return on Invested Capital | 0.94% |
Valuation & Multiples
| P/E Ratio | 219.05 |
|---|---|
| PEG | 33.97 |
| Price to Sales | 8.8 |
| Price to Book Ratio | 1.95 |
| Enterprise Value to Revenue | 7.41 |
| Enterprise Value to EBIT | 164.39 |
| Enterprise Value to Net Income | 236 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$0.19
Average shareholder expectationRevenue Estimate
$218.67 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$0.31
Average shareholder expectationRevenue Estimate
$181.35 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tellgen Corporation
683 employees
CEO: Jian Er Yao Tellgen Corporation is dedicated to the creation, manufacturing, and supply of in-vitro diagnostic (IVD) solutions, serving both the Chinese domestic market and a global clientele. Their extensive product catalog includes cancer detectio...